...
首页> 外文期刊>European urology >Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivityeurogenic overactive bladder: a systematic literature review.
【24h】

Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivityeurogenic overactive bladder: a systematic literature review.

机译:成人神经源性逼尿肌过度活动/神经源性膀胱过度活动的成人肉毒杆菌毒素A(肉毒杆菌)intrutrusor注射:系统的文献综述。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: This systematic literature review discusses the efficacy and safety of botulinum toxin type A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity (NDO) and urinary incontinence or overactive bladder symptoms of neurogenic origin (NOAB). METHODS: A MEDLINE and EMBASE search for clinical studies with botulinum toxin A injected into the detrusor of adults with NDO was performed. For several efficacy and safety variables data were extracted by one person and independently quality-controlled by another person. Extracted data were reviewed to propose recommendations for use in clinical practice based on level of evidence and expert opinion. RESULTS: A total of 18 articles evaluating the efficacy or safety of Botox in patients with NDO and incontinence/NOAB resistant to antimuscarinic therapy, with or without clean intermittent self-catheterisation (CIC), were selected. The amount of Botox injected was mostly 300 U, usually as 30 injections of 10 U/ml in the bladder (excluding the trigone) under cystoscopic guidance and with different types of anaesthesia. Most of the studies reported a significant improvement in clinical (approximately 40-80% of patients became completely dry between CICs) as well as urodynamic (in most studies mean maximum detrusor pressure was reduced to < or 40 cm H(2)O) variables and in the patients' quality of life, without major adverse events. CONCLUSIONS: Botox injections into the detrusor provide a clinically significant improvement in adults with NDO and incontinence/NOAB refractory to antimuscarinics. It seems to be very well tolerated. However, more adequately powered, well-designed, randomised, controlled studies evaluating the optimal dose, number and location of injections, impact on antimuscarinic regimen and CIC use, duration of effect, and when to perform repeat injections are warranted.
机译:目的:这篇系统的文献综述讨论了成年神经源性逼尿肌过度活动(NDO)和尿失禁或神经源性膀胱过度活动症状(NOAB)的成年人注射A型肉毒杆菌毒素(Botox)的有效性和安全性。方法:进行了MEDLINE和EMBASE搜索,以将N型成人成年逼尿肌注射肉毒杆菌毒素A进行临床研究。对于几个功效和安全性变量,数据由一个人提取,并由另一个人独立进行质量控制。审查提取的数据,以根据证据水平和专家意见提出用于临床实践的建议。结果:总共有18篇文章评估了肉毒杆菌毒素在NDO和尿失禁/ NOAB对抗毒蕈碱治疗耐药的患者中的有效性或安全性,无论是否采用干净的间歇性自导管(CIC)。注射的肉毒杆菌毒素的量大部分为300 U,通常是在膀胱镜引导下并以不同类型的麻醉在膀胱(不包括Trigone)中注射30次,每次10 U / ml。大多数研究报告说,临床上有显着改善(大约40-80%的患者在CIC之间完全干燥)和尿流动力学(在大多数研究中,最大逼尿肌压力降低至<或40 cm H(2)O)并且在患者的生活质量方面,没有重大不良事件。结论:向逼尿肌注射肉毒杆菌毒素可显着改善成年NDO和抗毒蕈碱难治性尿失禁/ NOAB的成年人。它似乎被很好地容忍了。但是,需要进行更充分的动力,精心设计的随机对照研究,评估最佳剂量,注射次数和位置,对抗毒蕈碱疗法和CIC使用的影响,作用时间以及何时进行重复注射。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号